Staphylococcus aureus continues to be a serious public health concern as S. aureus infections result in high morbidity and mortality rates (Turner et al., 2019). Although historically known as a nosocomial pathogen, there has been an increase in community-acquired (CA) S. aureus cases among both immunocompetent and immunocompromised groups (Tenover et al., 2006). These CA S. aureus strains often cause skin and soft tissue infections that can develop into invasive and systemic infections (Turner et al., 2019). Treatment of S. aureus infections is complicated due to the ability of this pathogen to evolve and/or acquire resistance to antibiotics (Malachowa and DeLeo, 2010). To combat these problems, we need to develop new prevention and therapeutic approaches including the characterization of new promising antimicrobial targets.Copper (Cu) is gaining popularity as an antimicrobial but killing or preventing the growth of microorganisms using Cu is an age-old technology (Dollwet and Sorenson, 1985;Grass et al., 2011). Copper is increasingly used as an intrinsic antibacterial and in metallic copper or copper-containing alloys on touch surfaces (Grass et al., 2011). Mammals also use Cu to help clear infections by increasing Cu loads at sites of inflammation (Beveridge et al., 1985;Hodgkinson and Petris, 2012). Cu accumulates within macrophage intracellular vesicles (Achard et al., 2012) and ultimately in phagosomes (Wagner et al., 2005). The addition of Cu to macrophages increases killing efficiency and genetic depletion of the Cu